Status and phase
Conditions
Treatments
About
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,256 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Chunlei Jin, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal